Hims stock launched by double digits Tuesday after the company inked a deal to offer Novo Nordisk‘s (NVO) weight-loss drug, Wegovy, on its telehealth platform.
The collaboration will allow people in the U.S. to access NovoCare Pharmacy directly through Hims & Hers Health‘s (HIMS) online platform. Patients can bundle all dose strengths of Wegovy with a Hims & Hers membership.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy? “We’ve always believed that if you center the customer, you can change the healthcare system,” Hims Chief Executive Andrew Dudum said in a written statement. “We’re doing that at scale and partnering with an industry leader who believes in the same future.”
On today’s stock market, Hims stock jumped more than 26% to 35.97 in early morning trades.
More to follow.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
IBD 50’s Top Seed, ADMA, Just Surged On A New FDA Approval
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
Looking For The Next Big Stock Market Winners? Start With These 3 Steps
IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today
Vertical Violations: Why You Should Recognize This Bear Market Indicator
